Gene patent fight over breast cancer test

2019-03-02 03:03:11

A ROW has erupted in Europe over a possible patent on a breast cancer test that might lead to some of the most vulnerable women being denied the test, while others get it for free. The test is for a specific mutation in the BRCA2 gene that predisposes women to breast cancer and is relatively common in Ashkenazi Jews. Although a previous patent on this and other BRCA2 mutations was overturned in February 2004 by the European Patent Office, the company that owned it – Myriad Genetics of Salt Lake City,